Additional details about BridgeBio Pharma, Inc.’s transthyretin amyloid cardiomyopathy (ATTR-CM) drug, acoramidis, from the Phase III ATTRibute-CM trial, suggest the drug is approvable, but do not answer questions about differentiation from competitor Pfizer Inc.’s Vyndamax/Vyndaqel (tafamidis) franchise or questions around partnering and financing for potential commercial launch.
BridgeBio ATTR-CM Data Ignite Discussion Around Financing, Partnerships
The company presented detailed data for acoramidis at the ESC meeting over the weekend, though some data points like time to first CV hospitalization have not yet reported out.
More from Clinical Trials
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
More from R&D
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.